During the year-end period, large pharmas secured clinical-stage oncology programs: AbbVie and Gilead announced separate deals to add targeted cancer drugs to their pipelines. AbbVie paid a large upfront to secure ex-China rights to a DLL3-targeting trispecific T-cell engager, while Gilead acquired rights to a polymerase theta (Polθ) inhibitor from Repare Therapeutics. Both agreements include multi-hundred-million-dollar potential milestones and royalties. Companies described the transactions as strategic additions to cell-engager and synthetic-lethality portfolios; analysts flagged the deals as examples of continued high-value biopharma M&A and licensing despite mixed clinical readouts elsewhere in the sector.